Skip to Content

Press Releases

Press Releases

Aug 21 2017
Intec Pharma Announces Closing of $57.5 Million Public Offering of Ordinary Shares
JERUSALEM, August 21, 2017 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ and TASE: NTEC) today announced the closing of its previously announced offering of approximately 12.2 million of its ordinary shares, at a public offering price of $4.70 per ordinary share, which included a full exercise by the
Aug 16 2017
Intec Pharma Announces Pricing of $50.0 Million Public Offering of Ordinary Shares
JERUSALEM, August 16, 2017 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ and TASE: NTEC) today announced the pricing of an underwritten public offering of approximately 10.6 million of its ordinary shares at a public offering price of $4.70 per ordinary share.
Aug 09 2017
Intec Pharma Reports Financial Results for the First Six Months of 2017
JERUSALEM, Aug. 9, 2017 /PRNewswire/ -- Intec Pharma Ltd. (Nasdaq: NTEC) (TASE: NTEC), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ (AP) platform technology, today reported financial results for the six months ended June 30, 2017.
Jul 27 2017
Intec Pharma Promotes Nadav Navon, Ph.D. to Chief Operating Officer
JERUSALEM, July 27, 2017 /PRNewswire/ --  Intec Pharma Ltd. (Nasdaq, TASE: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ (AP) platform technology, announces the promotion of Nadav Navon, Ph.D., Executive Vice
Jul 19 2017
Intec Pharma Granted Patent in Hong Kong for Accordion Pill™ Carbidopa / Levodopa
JERUSALEM, July 19, 2017 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ, TASE: NTEC), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill [ TM ]  platform technology, announces that the Patent Registry Intellectual Property Department of Hong
Jul 19 2017
Intec Pharma Granted Patent in Hong Kong for Accordion Pill™ Carbidopa / Levodopa
JERUSALEM, July 19, 2017 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ, TASE: NTEC), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, announces that the Patent Registry Intellectual Property Department of Hong Kong has
Jul 10 2017
Intec Pharma Appoints U.S. Life Sciences Executive and Vice Chairman Jeffrey A. Meckler as Chief Executive Officer
JERUSALEM, July 10, 2017 /PRNewswire/ -- Intec Pharma Ltd. (Nasdaq: NTEC, TASE: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, announces the appointment of Jeffrey A.
May 31 2017
Intec Pharma to Participate at Upcoming June Conferences
Intec Pharma Ltd. (Nasdaq:NTEC)(TASE:NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, announces that the company will participate at the following two upcoming June conferences: LD Micro Invitational Date and
May 24 2017
Intec Pharma Granted U.S. Patent for Accordion Pill™ Comprising Levodopa for Improved Treatment of Parkinson's Diseases Symptoms
JERUSALEM, May 24, 2017 /PRNewswire/ -- Intec Pharma Ltd. (Nasdaq: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, announces that the United States Patent and Trademark Office has granted the Company patent
May 03 2017
Intec Pharma Announces CEO Change
JERUSALEM, May 3, 2017 /PRNewswire/ -- Intec Pharma Ltd. (Nasdaq: NTEC, TASE: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, announces that Zeev Weiss, Chief Executive Officer and a Director of the Company,
Displaying 31 - 40 of 74